Bevacizumab in Hereditary Hemorrhagic Telangiectasia

被引：85

作者：

Bose, Prithviraj ^{[1
]}

Holter, Jennifer L. ^{[1
]}

Selby, George B. ^{[1
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 360卷 / 20期

关键词：

D O I：

10.1056/NEJMc0901421

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：2143 / 2144

页数：2

相关论文

共 6 条

[1] Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease
Abdalla, SA
Letarte, M
[J]. JOURNAL OF MEDICAL GENETICS, 2006, 43 (02) : 97 - 110
[2] Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab
Flieger, Dimitri
Hainke, Sabine
Fischbach, Wolfgang
[J]. ANNALS OF HEMATOLOGY, 2006, 85 (09) : 631 - 632
[3] Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
Mitchell, Andrew
Adams, Leon A.
Mac Uillan, Gerry
Tibballs, Jon
Driesen, Rohan Vanden
Delriviere, Luc
[J]. LIVER TRANSPLANTATION, 2008, 14 (02) : 210 - 213
[4] Sadick H, 2005, HAEMATOLOGICA, V90, P818
[5] Shovlin CL, 2000, AM J MED GENET, V91, P66, DOI 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO
[6] 2-P